New Modality

New modalities can target disease-causing pathways that were previously inaccessible to traditional drugs, opening up new avenues for treating difficult-to-treat diseases like cancer, neurodegenerative diseases, and genetic disorders. Many new modalities are designed to specifically target diseased cells or tissues, minimizing off-target effects, and improving the overall safety and tolerability of the treatment. New modalities often work through unique mechanisms of action, allowing them to overcome resistance pathways that can develop with traditional drugs. Some new modalities can be tailored to the individual patient's genetic makeup or disease profile, offering a more personalized approach to treatment. And new modalities often use novel delivery systems that can bring the therapeutic payload directly to the site of action, increasing the drug's effectiveness and reducing side effects. Biologics,  Adeno-Associated Viruses (AAVs), and Exosomes are all newer modalities currently being studied with HORIBA’s unique offering of all of Raman,Fluorescence,Particle Size Analysis, and microbial testing.